Today, Boston, USA-based Clade Therapeutics announced the acquisition of Gadeta, a Netherlands-based cell therapy company developing innovative gamma/delta (g/d) T-cell receptor (TCR)-based immunotherapies for cancer patients.
Actual financial terms of the acquisition have not been disclosed, other than that Clade said it has acquired all outstanding shares of Gadeta, making it a wholly-owned subsidiary of Clade, and that Gadeta shareholders will receive upfront and downstream economics.
Clade’s pipeline programs are focused on replicating the benefits of the autologous cell therapy products, while addressing their profound limitations – inconsistent quality, challenging patient logistics, and lack of scalability.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze